Verdant

Verdant Research provides independent, objective analysis to inform the future of U.S. prescription drug policy. We combine rigorous modeling with deep policy expertise to support smarter policy and business decisions in pharmaceutical markets.

What We Do

Clarity Across Complex Drug Policy Decisions

Verdant provides economic and policy expertise across the core forces shaping U.S. prescription drug markets.

Learn More

Policy Analysis & Development

Data Analytics & Modeling

Litigation & Expert Testimony

Recent Work

See All Work

April 2026 Accelerated Approval

Strengthening the FDA's Accelerated Approval Pathway: Progress and Unfinished Business

The prices of drugs and the innovation that leads to their availability are reliable sources of controversy in American public discourse. In 2023, the United States spent $723 billion on thousands of branded and generic prescription drugs approved by the Food and Drug Administration (FDA). 1-3 Few of these drugs generate as much public scrutiny […]

→

April 2026 Pricing Policy

Under the Magnifying Glass: A Wave of Drug Price Transparency

In the span of a single week in late January and early February 2026, 3 federal actions—by Congress, the Department of Labor (DOL), and the Federal Trade Commission (FTC)—brought transparency efforts to the forefront of drug pricing policy. Whereas recent reforms have centered on prices set by pharmaceutical companies, this new wave of provisions shifts […]

→

Lead with Evidence

Partner with Verdant for rigorous, objective economic analysis.

Objective Analysis.Real-World Impact.